Vergès B
Service Endocrinologie, Diabétologie et Maladies métaboliques CHU de Dijon, Hôpital du Bocage, F-21000 Dijon.
Ann Endocrinol (Paris). 2001 Feb;62(1 Pt 2):128-32.
Type 2 diabetic patients show frequent lipid abnormalities characterized by increased triglyceride and decreased HDL-cholesterol levels, but also by qualitative and metabolic abnormalities of all lipoproteins (VLDL, IDL, LDL et HDL). Treatment of diabetic hyperlipidemia is important in order to reduce the incidence of cardiovascular events, which is high in type 2 diabetes. Treatment with statins is recommended when hypercholesterolemia is associated with diabetes. But the efficacy of statins in the treatment of the typical diabetic hyperlipidemia (hypertriglycerideùmia, decreased HDL-cholesterol) remains to be demonstrated, since their effects on triglycerides and HDL-cholesterol is moderate. However, the new statins (cerivastatine, atorvastatine), which are more powerful to reduce hypertriglyceridemia could be useful for the treatment of diabetic hyperlipidemia. But, only on going clinical trials with statins in diabetic patients will be able to precise their possible efficacy on the prevention of cardiovascular disease.
2型糖尿病患者常出现脂质异常,其特征为甘油三酯升高和高密度脂蛋白胆固醇降低,所有脂蛋白(极低密度脂蛋白、中间密度脂蛋白、低密度脂蛋白和高密度脂蛋白)也存在质量和代谢异常。治疗糖尿病高脂血症对于降低2型糖尿病患者高发的心血管事件发生率很重要。当高胆固醇血症与糖尿病相关时,建议使用他汀类药物治疗。但他汀类药物治疗典型糖尿病高脂血症(高甘油三酯血症、高密度脂蛋白胆固醇降低)的疗效仍有待证实,因为它们对甘油三酯和高密度脂蛋白胆固醇的作用较为温和。然而,新型他汀类药物(西立伐他汀、阿托伐他汀)降低高甘油三酯血症的作用更强,可能对治疗糖尿病高脂血症有用。但是,只有正在进行的糖尿病患者他汀类药物临床试验才能明确它们对预防心血管疾病的可能疗效。